Rajiv Kaul is a portfolio manager and research analyst for Fidelity Investments. Fidelity Investments is a leading provider of investment management, retirement planning, portfolio guidance, brokerage, benefits outsourcing and other financial products and services to more than 20 million individuals, institutions and financial intermediaries.

Rajiv manages Fidelity Select Biotechnology Portfolio and Fidelity Advisor Biotechnology Fund. Mr. Kaul has spent 20 years at Fidelity.  During this period, he has been widely recognized for his leadership within the biotech industry by media outlets such as the Wall Street Journal, New York Times, Bloomberg, CNBC, USA Today, and Barrons to name a few.   He is often ranked among the top rated healthcare investors in the US.  In 2013, 2014 and 2015 Rajiv was the winner of the Lipper Award for best 3 yr risk-adjusted performance within the Biotechnology and Healthcare industry, adding to this the Best Fund over 5 years Lipper Fund Award for 2015.  Rajiv is a member of the Research Advisory Council at Massachusetts General Hospital (MGH). MGH is the teaching hospital for Harvard Medical School and is rated the No. 1 hospital in America by US News & World Report.

He is a graduate of Harvard University and worked at McKinsey & Company prior to joining Fidelity.